The annual incidence of invasive pneumococcal pneumonia per 100,000 people was 28.3 among persons aged between 65 and 74 years, 41.2 among persons aged between 75 and 84 years, and 65.4 among persons aged over 85 years.
The annual incidence of non-invasive pneumococcal pneumonia per 100,000 people was 409.3 among persons aged between 65 and 74 years, 943.5 among persons aged between 75 and 84 years, and 1,947.1 among persons aged over 85 years.
The probability of mortality of pneumococcal pneumonia was 12.8% for persons aged between 65 and 74 years, 19.9% for persons aged between 75 and 84 years, and 26.3% for persons aged over 85 years.
The incidence of invasive pneumococcal pneumonia causing hospitalisation per 100,000 people ranged from 164 among persons aged between 65 and 74 years to 779 among persons aged over 85 years.
The mean length of hospitalisation was 16.5 days for persons aged between 65 and 74 years, 19.1 days for persons aged between 75 and 84 years, and 20.7 days for persons aged over 85 years.
For persons aged between 65 and 74 years, the effectiveness of the vaccine was: 86% in year 1, 81% in year 2, 75% in year 3, 71% in year 4, 66% in year 5, and 61% in year 6.
For persons aged between 75 and 84 years the effectiveness of the vaccine was: 76% in year 1, 68% in year 2, 60% in year 3, 52% in year 4, 44% in year 5, and 36% in year 6.
For persons aged over 85 years the effectiveness of the vaccine was: 62% in year 1, 49% in year 2, 36% in year 3, 23% in year 4, 1% in year 5, and 0% in year 6.
The probability of adverse effects was rated as extremely rare, and was therefore not included in the model.